Titan Biotech Ltd

Titan Biotech Other Announcement

Titan Biotech has dispatched letters to shareholders with unregistered emails, providing web links to access the FY 2025-26 Annual Report and 34th AGM Notice.

Titan Biotech Annual Report

Titan Biotech filed its 34th Annual Report and AGM Notice for the financial year 2025-26. The AGM is scheduled for September 29, 2026.

Titan Biotech Dividend

Titan Biotech Limited has fixed September 22, 2026, as the record date for a final dividend of ₹0.50 per share. The payout remains subject to shareholder approval.

Titan Biotech Annual General Meeting

Titan Biotech Limited will hold its 34th Annual General Meeting on September 29, 2026. The company set September 22, 2026, as the record date for final dividend eligibility.

Titan Biotech Bonus Issue

Titan Biotech Limited approved a 1:4 bonus issue and increased its authorised share capital to Rs. 10.40 Crore. The bonus issue is subject to shareholder approval at the upcoming AGM.

Value

₹2.07 Cr

Titan Biotech Board Meeting Date

Titan Biotech Ltd has scheduled a board meeting on September 3, 2026, to consider a bonus share issue and plan the 34th Annual General Meeting.

Titan Biotech Q1 FY27 Results: Net Profit ₹10.9 Cr, Up 58.0% YoY

Titan Biotech Ltd reported revenue from operations of ₹59.2 Cr (+27.3% YoY) and net profit of ₹10.9 Cr (+58.0% YoY) for Q1 FY27.

Key figure

Net profit ₹10.9 Cr · +58.0% YoY

Titan Biotech Board Meeting Date

Titan Biotech Ltd will hold a board meeting on August 13, 2026, to approve unaudited financial results for the quarter ended June 30, 2026.

Titan Biotech Legal & Regulatory

Titan Biotech reported loss of 300 shares previously transferred to the IEPF. Claims must be submitted within 15 days as per Regulation 39(3).

Titan Biotech Board Meeting Outcome

Titan Biotech Ltd board approved re-appointing M/s Sanjay Kumar Garg & Associates as Cost Auditors for FY 2026-27. The appointment remains subject to shareholder ratification.

Execution

FY 2026-2027

Titan Biotech Q4 FY26 Results: Net Profit ₹6.7 Cr, Up 67.5% YoY

Titan Biotech Ltd reported revenue from operations of ₹48.8 Cr (+38.6% YoY) and net profit of ₹6.7 Cr (+67.5% YoY) for Q4 FY26.

Key figure

Net profit ₹6.7 Cr · +67.5% YoY

Titan Biotech Financial Results

Titan Biotech Limited approved its audited financial results for the fiscal year ended March 31, 2026. The Board also recommended a dividend of Rs. 0.50 per share.

Titan Biotech Board Meeting Date

Titan Biotech Limited scheduled a board meeting for May 30, 2026, to approve annual audited financial results and recommend dividends. Trading remains closed until June 1.

Titan Biotech Other Announcement

Titan Biotech Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by practicing company secretary Mr. Amit Anand, confirms the company's compliance with SEBI regulations and secretarial standards.

Titan Biotech Debt & Borrowing

Titan Biotech Limited confirmed it is not classified as a Large Corporate for the financial year ended March 31, 2026. The company reported zero outstanding long-term borrowings under the SEBI framework. This annual disclosure is a routine compliance requirement for listed entities regarding debt market borrowing norms.

Titan Biotech Other Announcement

Titan Biotech Ltd submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations for the period ended March 31, 2026. The Registrar and Share Transfer Agent, Beetal Financial, confirmed that security certificates received for dematerialization were processed, cancelled, and substituted in the register of members within the mandated 15-day timeline.